Lv6
3030 积分 2023-03-10 加入
Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity
10天前
已完结
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
21天前
已完结
Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer
21天前
已完结
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
22天前
已完结
Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
22天前
已完结
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
22天前
已完结
Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer
22天前
已完结
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors
22天前
已完结
Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy
22天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1个月前
已关闭
皖公网安备34019202002308
